This suggests that targeted tumour expression of the new hybrid IL15Igk results in tumour enrichment with CD8+ T and NK cells, and subsequent stimulation of their cytolytic activity against cancer (Steel et al, 2012). This evidence concerns the gene CD8A and cancer.